Detalhe da pesquisa
1.
Optoelectronic coherent Ising machine for combinatorial optimization problems.
Opt Lett
; 48(8): 2150-2153, 2023 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37058664
2.
Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
Cytotherapy
; 20(7): 952-963, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30180944
3.
A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer.
Breast Cancer Res Treat
; 156(2): 301-10, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26975189
4.
A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors.
Breast Cancer Res Treat
; 156(2): 319-30, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26993131
5.
NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient.
Haematologica
; 103(9): e424-e426, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29703727
6.
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.
Lancet Haematol
; 10(3): e191-e202, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36764323
7.
Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected].
J Transl Med
; 10: 28, 2012 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-22325452
8.
Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010".
J Transl Med
; 9: 32, 2011 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-21439082
9.
Expression of tumor-associated antigens in breast cancer subtypes.
Breast
; 49: 202-209, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31869767
10.
Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies.
BioDrugs
; 33(5): 515-537, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31363930
11.
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.
Cancer Immunol Res
; 7(1): 100-112, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30396908
12.
Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic.
ESMO Open
; 3(5): e000384, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30094070
13.
Celyad's novel CAR T-cell therapy for solid malignancies.
Curr Res Transl Med
; 66(2): 53-56, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29625833
14.
Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature.
ESMO Open
; 2(5): e000203, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29177094
15.
Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types.
BMJ Open
; 7(11): e017075, 2017 Nov 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29133316
16.
Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies.
J Natl Cancer Inst
; 94(19): 1484-93, 2002 Oct 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-12359857
17.
The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients.
Lung Cancer
; 101: 137-144, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27794402
18.
Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation Study.
J Thorac Oncol
; 11(12): 2208-2217, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27544054
19.
Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer.
Eur J Cancer
; 41(4): 555-63, 2005 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-15737560
20.
Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer.
J Thorac Oncol
; 10(10): 1458-67, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26309191